BioMarin Pharma (BMRN) Tops Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. OIG
5. NRIX
6. SUNS
7. ACI
8. SPY
9. SNDX
10. HUM

Go back to BioMarin Pharma (BMRN) Tops Q4 EPS

BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business

February 27, 2023 4:03 PM EST

VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 BillionIn 2023, More than 15% Growth in Total Revenues and Approximately 30% Growth in Net Income Expected Based on Mid-point of Today's Full-year Guidance; VOXZOGO Revenues Expected to More than DoubleROCTAVIAN European Commercial Launch and U.S. Launch Preparations Both Underway; 3-year Analysis from Phase 3 ROCTAVIAN Study in Adults with Severe Hemophilia A Recently Submitted to the FDA

Financial Highlights (in millions of U.S. dollars, except per share data,... More